Clinical Trials

Clinical trials are research studies that test whether new medical treatments, devices or strategies  are safe and effective.

People who volunteer for clinical trials play an active role in their own health care, often gain access to experimental treatments, and help others by improving and advancing medical care.

At Providence Cancer Institute, our scientists and physicians work closely together to make clinical trials a regular part of cancer care. Patients may take part in studies initiated by our translational researchers at the Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute, in addition to studies sponsored by the National Cancer Institute or pharmaceutical and biotechnology companies.

Our clinical trials team works directly with physicians to identify clinical trials appropriate for their patients’ specific stage of disease.

The goals of clinical research vary from trial to trial. Generally, they are designed to:

  • Improve prevention, early diagnosis and treatment of cancer
  • Discover whether a particular drug  or medical treatment is safe and effective
  • Advance the state of scientific and medical knowledge
  • Measure and improve the quality of life for patients and their families

Find cancer clinical trials available in Oregon in the list below. You may search by keyword or condition/disease, or browse using the page numbers and arrows. Find additional trials by using the search term “Oncology Multiple Tumor Sites". To learn more about a particular trial and qualification criteria, click the trial name and then the listed contact link, or talk with your physician.

Viewing Page 4 of 32 | Showing Results 16 - 20 of 157

A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have...

Gina Vaccaro, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)

The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination...

Gina Vaccaro, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line...

Gina Vaccaro, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

A Phase 3, Global Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma

To evaluate the efficacy of IMAB362 plus mFOLFOX6 compared with placebo plus mFOLFOX6 (as first-line treatment for metastatic disease) as measured...

Gina Vaccaro, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with Fluorouracil (5-FU) in...

Gina Vaccaro, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic
Viewing Page 4 of 32 | Showing Results 16 - 20 of 157